Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries.

Anibal Faúndes,Ellen Hardy,Q. Reyes,Laura Pastene,R. Portes-carrasco

DOI: https://doi.org/10.1016/0010-7824(81)90006-8

IF: 3.051

1981-10-01

Contraception

Abstract:

What problem does this paper attempt to address?

Current and future treatment for alcoholic‐related liver diseases

Eileen L. Yoon,Won Kim

DOI: https://doi.org/10.1111/jgh.16257

2023-06-11

Journal of Gastroenterology and Hepatology

Abstract:The socioeconomic burden of alcohol‐related liver disease has been increasing worldwide. Its prevalence is underestimated, and patients with alcohol‐related liver disease are rarely diagnosed in the earlier phase of the disease spectrum. Alcoholic hepatitis is a distinct syndrome with life‐threatening signs of systemic inflammation. In severe alcoholic hepatitis, prednisolone is indicated as the first‐line treatment even with the possibility of various complications. Early liver transplantation can be another option for highly selected patients with a null response to prednisolone. Most importantly, abstinence is the mainstay of long‐term care, but relapse is frequent among patients. Recent findings on the pathogenesis of alcoholic hepatitis have enabled us to discover new therapeutic targets. Preventing hepatic inflammation, reducing oxidative stress, improving gut dysbiosis, and enhancing liver regeneration are the main targets of emerging therapies. Herein, we review the pathogenesis, current treatment, and barriers to successful clinical trials of alcoholic hepatitis. Additionally, clinical trials for alcoholic hepatitis, either ongoing or recently completed, will be briefly introduced.

gastroenterology & hepatology
Pharmacotherapy of alcoholic liver disease in clinical practice

V Rosato,L Abenavoli,A Federico,M Masarone,M Persico

DOI: https://doi.org/10.1111/ijcp.12764

Abstract:Aims: Alcohol is the most commonly used addictive substance and alcoholic liver disease (ALD) is a major cause of chronic liver disease worldwide, responsible for 47.9% of all liver chronic deaths. Despite ALD has a significant burden on the health, few therapeutic advances have been made in the last 40 years, particularly in the long-term management of these patients. Methods: we searched in PubMed, Scopus, Google Scholar, and MEDLINE databases to identify relevant English language publications focused on long-term therapy of ALD. Results: From the huge literature on this topic, including about 755 studies, 75 were selected as eligible including clinical trials and meta-analysis. Conclusions: Abstinence remains the cornerstone of ALD therapy but it is also the most difficult therapeutic target to achieve and the risk of recidivism is very high at any time. Several drugs (disulfiram, naltrexone, acamprosate, sodium oxybate) have proven to be effective to prevent alcohol relapse and increase the abstinence, although the psychotherapeutic support remains crucial. Baclofen seems to be effective to improve abstinence, showing an excellent safety and tolerability. ALD is often complicated by a state of malnutrition, which is related to a worst mortality. A nutritional therapy may improve survival in cirrhotic patients, reversing muscle wasting, weight loss and specific nutritional deficiencies. While in aggressive forms of alcoholic hepatitis are recommended specific drug treatments, including glucocorticoids or pentoxifylline, for the long-term treatment of ALD, specific treatments aimed at stopping the progression of fibrosis are not yet approved, but there are some future perspective in this field, including probiotics and antibiotics, caspase inhibitors, osteopontin and endocannabinoids.
Learning Hands-on and by Trial & Error with Data Curation Profiles

D. S. Brandt

Abstract:The Data Curation Profiles Toolkit can be used in several ways to capture requirements for data sets, as articulated by researchers. As a flexible instrument it can facilitate dialog between librarians and researchers to discuss data concerns, current data workflow, and possible outcomes for the future. As a structured tool it can help identify areas of concern and need, to begin to making informed decisions about the data. Published Profiles offer insight into similarities and variations in data and data workflow, across multiple research areas or sub-disciplines. Designed as a tool for practitioners, it can help build knowledge and skill through application. Librarians who have completed Profiles have found the process to improve their comfort, increase their confidence, and build competencies in working with researchers. Mapping use of the Profiles Toolkit to the DigCurV Curriculum Framework can help identify strengths and weaknesses in what is currently a hands-on, trial and error self-
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy

Vetriselvan Subramaniyan,Srikumar Chakravarthi,Ravindran Jegasothy,Wu Yuan Seng,Neeraj Kumar Fuloria,Shivkanya Fuloria,Iswar Hazarika,Anju Das

DOI: https://doi.org/10.1016/j.toxrep.2021.02.010

2021-01-01

Toxicology Reports

Abstract:One of the global burdens of health care is an alcohol-associated liver disease (ALD) and liver-related death which is caused due to acute or chronic consumption of alcohol. Chronic consumption of alcohol damage the normal defense mechanism of the liver and likely to disturb the gut barrier system, mucosal immune cells, which leads to decreased nutrient absorption. Therapy of ALD depends upon the spectrum of liver injury that causes fatty liver, hepatitis, and cirrhosis. The foundation of therapy starts with abstinence from alcohol. Corticosteroids are used for the treatment of ALD but due to poor acceptance, continuing mortality, and identification of tumor necrosis factor-alpha as an integral component in pathogenesis, recent studies focus on pentoxifylline and, antitumor necrosis factor antibody to neutralize cytokines in the therapy of severe alcoholic hepatitis. Antioxidants also play a significant role in the treatment but till today there is no universally accepted therapy available for any stage of ALD. The treatment aspects need to restore the gut functions and require nutrient-based treatments to regulate the functions of the gut system and prevent liver injury. The vital action of saturated fatty acids greatly controls the gut barrier. Overall, this review mainly focuses on the mechanism of alcohol-induced metabolic dysfunction, contribution to liver pathogenesis, the effect of pregnancy, and targeted therapy of ALD.
Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

David W. Crabb,Gene Y. Im,Gyongyi Szabo,Jessica L. Mellinger,Michael R. Lucey

DOI: https://doi.org/10.1002/hep.30866

IF: 17.298

2020-01-01

Hepatology

Abstract:Alcoholic liver disease (ALD) represents a spectrum of liver injury resulting from alcohol use, ranging from hepatic steatosis to more advanced forms including alcoholic hepatitis (AH), alcoholic cirrhosis (AC), and acute alcoholic hepatitis presenting as acute on chronic liver failure (ACLF). ALD is a major cause of liver disease worldwide, both on its own and as a co‐factor in the progression of chronic viral hepatitis, nonalcoholic fatty liver disease (NAFLD), iron overload and other liver diseases. ALD develops through several stages, beginning with hepatic steatosis, and, in some individuals, gradually progressing through alcoholic hepatitis (the histological correlate of which is alcoholic steatohepatitis), culminating in cirrhosis (Figure 1). Progression through these various stages is dependent upon continued heavy alcohol consumption and other risk factors, including female sex, genetic susceptibility, diet, and comorbid liver disease. ALD carries a significant stigma in society. It is increasingly recognized by providers that patients and their families seek to reduce the stigma of alcoholic liver disease, and a change from the term "alcoholic" to "alcohol‐related" will help; thus, alcohol‐related liver disease, alcohol‐related steatohepatitis, and alcohol‐related cirrhosis are suggested, retaining the familiar abbreviations (ALD, ASH, and AC, respectively). Due to longstanding usage, the term alcoholic hepatitis (AH) will likely persist.This article is protected by copyright. All rights reserved.

gastroenterology & hepatology
ACG Clinical Guideline: Alcohol-Associated Liver Disease

Loretta L. Jophlin,Ashwani K. Singal,Ramon Bataller,Robert J. Wong,Bryan G. Sauer,Norah A. Terrault,Vijay H. Shah

DOI: https://doi.org/10.14309/ajg.0000000000002572

2024-01-05

The American Journal of Gastroenterology

Abstract:Alcohol-associated liver disease (ALD) is the most common cause of advanced hepatic disease and frequent indication for liver transplantation worldwide. With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden. The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension. Compared with those with other etiologies of liver disease, patients with ALD progress faster and more often present at an advanced stage. A unique phenotype of advanced disease is alcohol-associated hepatitis (AH) presenting with rapid onset or worsening of jaundice, and acute on chronic liver failure in severe forms conveying a 1-month mortality risk of 20%–50%. The model for end stage disease score is the most accurate score to stratify AH severity (>20 defined as severe disease). Corticosteroids are currently the only available therapeutic with proven efficacy for patients with severe AH, providing survival benefit at 1 month in 50%–60% of patients. Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD). As patients with ALD are rarely treated for AUD, strategies are needed to overcome barriers to AUD treatment in patients with ALD and to promote a multidisciplinary integrated care model with hepatology, addiction medicine providers, and social workers to comprehensively manage the dual pathologies of liver disease and of AUD. Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH, who are unresponsive to medical therapy and have a low risk of relapse to posttransplant alcohol use. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the American College of Gastroenterology Practice Parameters Committee.

gastroenterology & hepatology
Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action

Lamia Y. Haque,Paola Zuluaga,Robert Muga,Daniel Fuster

DOI: https://doi.org/10.1186/s13722-024-00448-8

2024-03-21

Addiction Science & Clinical Practice

Abstract:Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. Besides, the presence of liver cirrhosis can complicate pharmacological treatment choices. In this review, we discuss established and innovative treatment strategies to treat unhealthy alcohol use in patients with alcohol-associated liver disease. We also describe the experience of our own institutions, Hospital Universitari Germans Trias i Pujol in Badalona (Spain) and Yale-New Haven Health and Yale Medicine (Connecticut. United States of America).

substance abuse
Alcohol use disorder in community management of chronic liver diseases

Lorenzo Leggio,Jessica L. Mellinger

DOI: https://doi.org/10.1002/hep.32531

IF: 17.298

2022-04-29

Hepatology

Abstract:Rising rates of alcohol use disorder (AUD) combined with increases in alcohol-related liver disease (ALD) and other liver disease have resulted in the need to develop alcohol management strategies at all levels of patient care. For those with pre-existing liver disease, whether ALD or others, attention to alcohol use treatment and abstinence becomes critical to avoiding worsening liver-related consequences. Modalities to help patients reduce or stop alcohol include screening/brief intervention/referral to treatment, various therapeutic modalities including cognitive behavioral therapy, motivational enhancement therapy and 12-step facilitation, and alcohol relapse prevention medications. Harm reduction approaches versus total abstinence may be considered, but for those with existing ALD, particularly advanced ALD (cirrhosis or acute alcoholic hepatitis), total abstinence from alcohol is the recommendation, given clear data that ongoing alcohol use worsens mortality and liver-related morbidity. For certain populations, alcohol cessation is even more critically important. For those with hepatitis C or NAFLD, alcohol use accelerates negative liver-related outcomes. In women, alcohol use accelerates liver damage and results in worsened liver-related mortality. Efforts to integrate AUD and liver disease care are urgently needed and can occur at several levels, with establishment of multidisciplinary ALD clinics for fully integrated co-management as an important goal.

gastroenterology & hepatology
Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Timothy R Morgan

DOI: https://doi.org/10.1016/j.cld.2024.06.014

Abstract:Several treatments have shown efficacy in preliminary alcohol-associated hepatitis trials. Interleukin-22 improved Model of End-stage Liver Disease score and aminotransferases in a phase II trial. The endogenous cholesterol derivative, larsucosterol, improved outcomes in a multi-center United States or European phase II trial. The antioxidants N-acetylcysteine and metadoxine improved survival in large trials. Trials from India report improved survival with granulocyte-colony stimulating factor, as well as improved outcome among patients receiving fecal microbiota transfer. Translational studies suggest that phage treatment of cytolytic Enterococcus faecalis may reduce liver injury.
Alcoholic Hepatitis: A Review

Nooshin Hosseini,Julia Shor,Gyongyi Szabo

DOI: https://doi.org/10.1093/alcalc/agz036

2019-06-20

Alcohol and Alcoholism

Abstract:Abstract Alcoholic liver disease (ALD) represents a spectrum of injury, ranging from simple steatosis to alcoholic hepatitis to cirrhosis. Regular alcohol use results in fatty changes in the liver which can develop into inflammation, fibrosis and ultimately cirrhosis with continued, excessive drinking. Alcoholic hepatitis (AH) is an acute hepatic inflammation associated with significant morbidity and mortality that can occur in patients with steatosis or underlying cirrhosis. The pathogenesis of ALD is multifactorial and in addition to genetic factors, alcohol-induced hepatocyte damage, reactive oxygen species, gut-derived microbial components result in steatosis and inflammatory cell (macrophage and neutrophil leukocyte) recruitment and activation in the liver. Continued alcohol and pro-inflammatory cytokines induce stellate cell activation and result in progressive fibrosis. Other than cessation of alcohol use, medical therapy of AH is limited to prednisolone in a subset of patients. Given the high mortality of AH and the progressive nature of ALD, there is a major need for new therapeutic intervention for this underserved patient population.

substance abuse
Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Ali Wakil,Mumtaz Niazi,Mohamad A Meybodi,Nikolaos T Pyrsopoulos

DOI: https://doi.org/10.1016/j.jceh.2022.06.012

Abstract:The incidence of alcoholic-associated hepatitis (AH) is increasing. The treatment options for severe AH (sAH) are scarce and limited to corticosteroid therapy which showed limited mortality benefit in short-term use only. Therefore, there is a dire need for developing safe and effective therapies for patients with sAH and to improve their high mortality rates.This review article focuses on the current novel therapeutics targeting various mechanisms in the pathogenesis of alcohol-related hepatitis. Anti-inflammatory agents such as IL-1 inhibitor, Pan-caspase inhibitor, Apoptosis signal-regulating kinase-1, and CCL2 inhibitors are under investigation. Other group of agents include gut-liver axis modulators, hepatic regeneration, antioxidants, and Epigenic modulators. We describe the ongoing clinical trials of some of the new agents for alcohol-related hepatitis. Conclusion: A combination of therapies was investigated, possibly providing a synergistic effect of drugs with different mechanisms. Multiple clinical trials of novel therapies in AH remain ongoing. Their result could potentially make a difference in the clinical course of the disease. DUR-928 and granulocyte colony-stimulating factor had promising results and further trials are ongoing to evaluate their efficacy in the large patient sample.
Guidelines of prevention and treatment for alcoholic liver disease (2018, China).

You Ming Li,Jian Gao Fan

DOI: https://doi.org/10.1111/1751-2980.12687

2019-01-01

Journal of Digestive Diseases

Abstract:Alcoholic liver disease (ALD), induced by long-term heavy alcohol consumption, encompasses a progressive clinical-histological spectrum of liver injuries from simple fatty liver to alcoholic hepatitis, hepatic fibrosis and cirrhosis. Excessive alcohol consumption may lead to extensive hepatocellular necrosis, and in severe cases to liver failure.
Alcohol or Gut Microbiota: Who Is the Guilty?

Marica Meroni,Miriam Longo,Paola Dongiovanni

DOI: https://doi.org/10.3390/ijms20184568

IF: 5.6

2019-09-14

International Journal of Molecular Sciences

Abstract:Alcoholic liver disease (ALD), a disorder caused by excessive alcohol intake represents a global health care burden. ALD encompasses a broad spectrum of hepatic injuries including asymptomatic steatosis, alcoholic steatohepatitis (ASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The susceptibility of alcoholic patients to develop ALD is highly variable and its progression to more advanced stages is strongly influenced by several hits (i.e., amount and duration of alcohol abuse). Among them, the intestinal microbiota and its metabolites have been recently identified as paramount in ALD pathophysiology. Ethanol abuse triggers qualitative and quantitative modifications in intestinal flora taxonomic composition, mucosal inflammation, and intestinal barrier derangement. Intestinal hypermeability results in the translocation of viable pathogenic bacteria, Gram-negative microbial products, and pro-inflammatory luminal metabolites into the bloodstream, further corroborating the alcohol-induced liver damage. Thus, the premise of this review is to discuss the beneficial effect of gut microbiota modulation as a novel therapeutic approach in ALD management.

biochemistry & molecular biology,chemistry, multidisciplinary
Nutritional and microbiota-based therapeutic intervention for alcohol-associated liver disease: Pathogenesis to therapeutic insights

Shagun Rangra,Dhwani Rana,Arvee Prajapati,Derajram Benival,Pradeep Dwivedi,Amit Mandoli

DOI: https://doi.org/10.1016/j.lfs.2024.122852

IF: 6.78

2024-06-24

Life Sciences

Abstract:Alcohol-associated liver disease (ALD) manifests as a consequence of prolonged and excessive alcohol consumption. This disease is closely associated with the interplay between gut health and liver function, which can lead to complex pathophysiological changes in the body. This review offers a comprehensive exploration of ALD's multifaceted nature, with a keen focus on its pathogenesis and the potential of nutritional and microbiota-based therapies. Insights derived from diverse case studies are utilized to shed light on how interventions can rebalance the gut microbiome and enhance liver function in ALD patients. Furthermore, the feasibility of liver transplantation and stem cell therapy as ultimate measures for ALD has been discussed, with acknowledgment of the inherent risks and challenges accompanying them. ALD's complexity underscores the necessity for a thorough understanding of its etiology and progression to devise effective treatments that mitigate its profound impact on an individual's health.

pharmacology & pharmacy,medicine, research & experimental
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting

Matias A Avila,Jean-François Dufour,Alexander L Gerbes,Fabien Zoulim,Ramon Bataller,Patrizia Burra,Helena Cortez-Pinto,Bin Gao,Ian Gilmore,Philippe Mathurin,Christophe Moreno,Vladimir Poznyak,Bernd Schnabl,Gyongyi Szabo,Maja Thiele,Mark R Thursz

DOI: https://doi.org/10.1136/gutjnl-2019-319720

IF: 24.5

2019-12-26

Gut

Abstract:Alcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the new therapeutic strategies tested in recently published or undergoing clinical trials spur scientific interest in this area. In April 2019, Gut convened a round table panel of experts during the European Association for the Study of the Liver International Liver Congress in Vienna to discuss critical and up-to-date issues and clinical trial data regarding ALD, its epidemiology, diagnosis, management, pathomechanisms, possible future treatments and prevention. This paper summarises the discussion and its conclusions.

gastroenterology & hepatology
Targeting Inflammation for the Treatment of Alcoholic Liver Disease.

Ming-Jiang Xu,Zhou,Richard Parker,Bin Gao

DOI: https://doi.org/10.1016/j.pharmthera.2017.06.007

2017-01-01

Abstract:Alcoholic liver disease (ALD) is a leading cause of chronic liver disease with a wide spectrum of manifestations including simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Liver injury in ALD is caused by chronic inflammation, which has been actively investigated as a therapeutic target for the treatment of ALD for over the last four decades. In this review, we summarize a wide variety of inflammatory mediators that have been shown to contribute to the pathogenesis of ALD, and discuss the therapeutic potential of these mediators for the treatment of ALD.
Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease

Josiah E Hardesty,Craig J McClain

DOI: https://doi.org/10.1016/j.cld.2024.06.018

Abstract:Patients with alcohol-associated liver disease (ALD) consume large amounts of empty calories and are at risk for malnutrition. Malnutrition can present with micro- or macro-nutrient deficiencies. The standard-of-care drug treatment for severe alcohol-associated hepatitis (AH) is corticosteroids. While still in the standard treatment there are limitations in efficacy and certain patients do not respond to treatment (Lille score ≥.45). This article will focus on important concepts related to nutrition and ALD and on recent findings on predicting corticosteroid response and prognosis for AH patients.
New Drug Targets for Alcoholic Liver Disease

Mingjiang Xu,Binxia Chang,Stephanie Mathews,Bin Gao

DOI: https://doi.org/10.1007/s12072-014-9516-x

IF: 9.029

2014-01-01

Hepatology International

Abstract:Alcoholic liver disease (ALD) represents a spectrum of disorders, ranging from simple steatosis to severe alcoholic hepatitis and cirrhosis. The severe form of ALD comprises multiple problems in the liver, including inflammation, hepatocellular damage, fibrosis, and impaired liver regeneration, and likely requires combinational therapies. In this review, we discuss recently identified therapeutic targets that inhibit inflammation, ameliorate hepatocyte death, and promote liver repair in ALD, with a focus on our recent studies on the immunosuppressive drug prednisolone and the hepatoprotective cytokine interleukin-22. Clinical trials examining prednisolone plus interleukin-22 therapy for severe alcoholic hepatitis are currently under consideration.
Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease

Silvia Andaloro,Fabrizio Mancuso,Luca Miele,Giovanni Addolorato,Antonio Gasbarrini,Francesca Romana Ponziani

DOI: https://doi.org/10.3390/nu16050613

IF: 5.9

2024-02-24

Nutrients

Abstract:Although alcohol is one of the most important etiologic agents in the development of chronic liver disease worldwide, also recognized as a promoter of carcinogenesis, several studies have shown a beneficial effect of moderate consumption in terms of reduced cardiovascular morbidity and mortality. Whether this benefit is also present in patients with liver disease due to other causes (viral, metabolic, and others) is still debated. Although there is no clear evidence emerging from guidelines and scientific literature, total abstention from drinking is usually prescribed in clinical practice. In this review, we highlight the results of the most recent evidence on this controversial topic, in order to understand the effect of mild alcohol use in this category of individuals. The quantification of alcohol intake, the composition of the tested populations, and the discrepancy between different works in relation to the outcomes represent important limitations emerging from the scientific literature. In patients with NAFLD, a beneficial effect is demonstrated only in a few works. Even if there is limited evidence in patients affected by chronic viral hepatitis, a clear deleterious effect of drinking in determining disease progression in a dose-dependent manner emerges. Poor data are available about more uncommon pathologies such as hemochromatosis. Overall, based on available data, it is not possible to establish a safe threshold for alcohol intake in patients with liver disease.

nutrition & dietetics
Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease

Xiaoqin Wu,Xiude Fan,Tatsunori Miyata,Adam Kim,Christina K. Cajigas-Du Ross,Semanti Ray,Emily Huang,Moyinoluwa Taiwo,Rakesh Arya,Jianguo Wu,Laura E. Nagy

DOI: https://doi.org/10.1146/annurev-pathmechdis-031521-030435

2023-01-25

Abstract:Alcohol-associated liver disease (ALD) is one of the major diseases arising from chronic alcohol consumption and is one of the most common causes of liver-related morbidity and mortality. ALD includes asymptomatic liver steatosis, fibrosis, cirrhosis, and alcohol-associated hepatitis and its complications. The progression of ALD involves complex cell-cell and organ-organ interactions. We focus on the impact of alcohol on dysregulation of homeostatic mechanisms and regulation of injury and repair in the liver. In particular, we discuss recent advances in understanding the disruption of balance between programmed cell death and prosurvival pathways, such as autophagy and membrane trafficking, in the pathogenesis of ALD. We also summarize current understanding of innate immune responses, liver sinusoidal endothelial cell dysfunction and hepatic stellate cell activation, and gut-liver and adipose-liver cross talk in response to ethanol. In addition,we describe the current potential therapeutic targets and clinical trials aimed at alleviating hepatocyte injury, reducing inflammatory responses, and targeting gut microbiota, for the treatment of ALD.

pathology

Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries.

Current and future treatment for alcoholic‐related liver diseases

Pharmacotherapy of alcoholic liver disease in clinical practice

Learning Hands-on and by Trial & Error with Data Curation Profiles

Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

ACG Clinical Guideline: Alcohol-Associated Liver Disease

Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action

Alcohol use disorder in community management of chronic liver diseases

Emerging Pharmacologic Treatments for Alcohol-Associated Hepatitis: Current Status and Future Landscape

Alcoholic Hepatitis: A Review

Emerging Pharmacotherapies in Alcohol-Associated Hepatitis

Guidelines of prevention and treatment for alcoholic liver disease (2018, China).

Alcohol or Gut Microbiota: Who Is the Guilty?

Nutritional and microbiota-based therapeutic intervention for alcohol-associated liver disease: Pathogenesis to therapeutic insights

Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting

Targeting Inflammation for the Treatment of Alcoholic Liver Disease.

Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease

New Drug Targets for Alcoholic Liver Disease

Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease

Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease